2004
DOI: 10.1002/cbic.200300800
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of Metal‐Carbonyl–Dendrimer–Antibody Immunoconjugates: Towards a New Format for Carbonyl Metallo Immunoassay

Abstract: We report the preparation of metal-carbonyl-dendrimer-antibody conjugates. These metal-carbonyl-multilabeled antibodies are designed to be used in a new solid-phase-format carbonyl metallo immunoassay (CMIA). A fourth-generation polyamidoamine dendrimer was labeled with 10-25 (eta5-cyclopentadienyl)iron dicarbonyl (eta1-N-succinimidyl) entities. An antibody was chemically modified at its carbohydrate chains by a site-directed process used to preserve the antigen-antibody binding site. The antibody was then cou… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
32
0

Year Published

2007
2007
2012
2012

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 34 publications
(32 citation statements)
references
References 43 publications
0
32
0
Order By: Relevance
“…Therefore, to maximize drug loading while minimizing the deleterious effects on the biological integrity of the host antibody, an attractive approach is to use a linker molecule, such as a dendrimer, that can be highly conjugated (or internally loaded) with drug while modifying only a single site on the surface of the antibody [147]. Methodology to covalently attach antibodies to dendrimers that preserve the activity of the antigen-antibody binding site [148,149], e.g., by chemical modification of their carbohydrates and subsequent linkage to PAMAM [150], has opened the door for the inclusion of dendrimers in immunotherapy [151,152], thereby enhancing the future prospects of this chronically ''almost-there'' strategy. The synthetic ability to attach both a tumor-targeting antibody and a potent payload of anticancer drugs to the same dendritic molecule provides a platform for multifunctional nano-scale drug delivery devices (Fig.…”
Section: Targeting By Monoclonal Antibodiesmentioning
confidence: 99%
“…Therefore, to maximize drug loading while minimizing the deleterious effects on the biological integrity of the host antibody, an attractive approach is to use a linker molecule, such as a dendrimer, that can be highly conjugated (or internally loaded) with drug while modifying only a single site on the surface of the antibody [147]. Methodology to covalently attach antibodies to dendrimers that preserve the activity of the antigen-antibody binding site [148,149], e.g., by chemical modification of their carbohydrates and subsequent linkage to PAMAM [150], has opened the door for the inclusion of dendrimers in immunotherapy [151,152], thereby enhancing the future prospects of this chronically ''almost-there'' strategy. The synthetic ability to attach both a tumor-targeting antibody and a potent payload of anticancer drugs to the same dendritic molecule provides a platform for multifunctional nano-scale drug delivery devices (Fig.…”
Section: Targeting By Monoclonal Antibodiesmentioning
confidence: 99%
“…This is a preliminary work, as our final objective is to label AV with metallocarbonyl PAMAM dendrimers, as part of our ongoing development of Carbonyl Metallo Immuno Assay. [8] …”
Section: Introductionmentioning
confidence: 97%
“…The ethylenic bond of the maleimidato ligand in these complexes is readily attacked by nucleophiles such as thiols, amines or imidazoles. These reactions can be used to introduce IR-detectable moieties on peptides and proteins with potential applications in immunoassays [6][7][8][9][10].…”
Section: Introductionmentioning
confidence: 99%